You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lymphoma, B-Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, B-Cell Trial in San Antonio (Roflumilast)

Active, not recruiting
  • Lymphoma, B-Cell
  • San Antonio, Texas
    Mays Cancer Center, UT Health San Antonio
Mar 9, 2022

TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System

Completed
  • Lymphoma, B-Cell
    • Montpellier, France
      Uh Montpellier
    Nov 12, 2021

    Lymphoma, B-Cell Trial (TAC01-CD19)

    Withdrawn
    • Lymphoma, B-Cell
    • TAC01-CD19
    • (no location specified)
    Feb 7, 2022

    B-cell Non Hodgkin's Lymphoma Trial (HLX01, Rituximab)

    Completed
    • B-cell Non Hodgkin's Lymphoma
    • (no location specified)
    May 4, 2022

    Lymphoma, B-Cell Trial in Guangzhou (Rituximab Biosimilar, Pegylated Interferon a-2b)

    Recruiting
    • Lymphoma, B-Cell
    • Rituximab Biosimilar
    • Pegylated Interferon α-2b
    • Guangzhou, Guangdong, China
      Department of Medical Oncology, Sun Yat-sen University Cancer Ce
    Apr 6, 2022

    Non-hodgkin Lymphoma,B Cell Trial in Shenzhen (Allogeneic CD19 CR-T cell)

    Recruiting
    • Non-hodgkin Lymphoma,B Cell
    • Allogeneic CD19 CR-T cell
    • Shenzhen, Guangdong, China
      Li Yu
    Nov 22, 2021

    B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Lymphoma (B-ALL) Trial (PIT565)

    Not yet recruiting
    • B-cell Non-Hodgkin Lymphoma (B-NHL)
    • B-cell Acute Lymphoblastic Lymphoma (B-ALL)
    • PIT565
    • (no location specified)
    Jun 13, 2022

    Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

    Recruiting
    • Relapsed/Refractory Diffuse Large B Cell Lymphoma
    • Glofitamab, Poseltinib, Lenalidomide
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    May 30, 2022

    Relapsed Diffuse Large B-cell Lymphoma Trial in Detroit (loncastuximab tesirine)

    Recruiting
    • Relapsed Diffuse Large B-cell Lymphoma
    • loncastuximab tesirine
    • Detroit, Michigan
      Barbara Ann Karmanos Cancer Institute
    Jun 24, 2022

    Mantle Cell Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma Trial in Hangzhou (RD14-01 cell infusion)

    Recruiting
    • Mantle Cell Lymphoma
    • +2 more
    • RD14-01 cell infusion
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of Medicine, Zhejiang Uni
    Jul 6, 2022

    B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

    Not yet recruiting
    • B-cell Non-Hodgkin Lymphoma
    • +4 more
    • (no location specified)
    May 6, 2022

    Lymphoma, Non-Hodgkin Lymphoma, B-Cell Trial (BAFF CAR-T)

    Not yet recruiting
    • Lymphoma, Non-Hodgkin Lymphoma, B-Cell
    • BAFF CAR-T
    • (no location specified)
    Aug 16, 2022

    Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    May 4, 2022

    Diffuse Large B-cell Lymphoma Trial in Toulouse (Patient with histologically confirmed diffuse large B-cell lymphoma with a

    Recruiting
    • Diffuse Large B-cell Lymphoma
    • Patient with histologically confirmed diffuse large B-cell lymphoma with a planned first line treatment by R-CHOP.
    • Toulouse, France
      Institut Universitaire du Cancer Toulouse - Oncopole
    Mar 28, 2022

    High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)

    Not yet recruiting
    • High-grade B-cell Lymphoma
    • +8 more
    • Sepantronium Bromide
    • Busan, Korea, Republic of
    • +5 more
    Feb 27, 2022

    Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

    Recruiting
    • Follicular Lymphoma
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jul 20, 2022

    B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

    Not yet recruiting
    • B Cell Lymphoma
    • +5 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jul 27, 2022

    Diffuse Large B Cell Lymphoma Trial (Rituximab, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    Apr 24, 2022

    Large B-cell Lymphoma Trial in Shanghai (BZ019)

    Recruiting
    • Large B-cell Lymphoma
    • BZ019
    • Shanghai, Shanghai, China
      Shanghai Mengchao Cancer Hospital
    Jul 21, 2022

    Diffuse Large B Cell Lymphoma, CAR-T, Radiotherapy Trial (ultra-fraction radiotherapy)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • ultra-fraction radiotherapy
    • (no location specified)
    Aug 22, 2022

    Diffuse Large B Cell Lymphoma, CNS Metastasis Trial in Herlev

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Central Nervous System Metastasis
      • Herlev, Capital Region, Denmark
        Herlev Hopital
      Mar 21, 2022

      Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)

      Recruiting
      • Lymphoma
      • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Aug 20, 2022

      Diffuse Large B Cell Lymphoma Trial in Shanghai (zanubrutinib)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Mar 13, 2022

      Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker

      Recruiting
      • Follicular Lymphoma
      • +2 more
      • Laboratory Biomarker Analysis
      • Pembrolizumab
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Apr 11, 2022

      B-cell Lymphoma Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)

      Completed
      • B-cell Lymphoma
      • CD19/CD20 Dual-CAR-T cells
      • Sanhe, Hebei, China
        Hebei Yanda Ludaopei Hospital
      Mar 6, 2022